Cancer Treatment Reviews
Volume 29, Issue 1 , Pages 73-75 , February 2003

Immunochemotherapy with OK-432 may improve survival for people with curatively resected gastric cancer: Abstracted from: Sakamoto J, Teramukai S, Nakazato H et al. Efficacy of adjuvant immunochemotherapy with OK-432 for patients with curatively resected gastric cancer: a meta-analysis of centrally randomized controlled clinical trials. Journal of Immunotherapy 2002; 25: 405–12.

References 

  1. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J. Clin. 1999;49:33–64
  2. Maehara Y, Kakeji Y, Koga T, et al.  Therapeutic value of lymph node dissection and the clinical outcome for patients with gastric cancer. Surgery. 2002;131:S85–S91
  3. Gastric Cancer (PDQ®): Treatment Health Professional Version (Date last modified: 10/2002): http://www.cancer.gov/
  4. Allum WH, Griffin SM, Watson A, et al.  Guidelines for the management of oesophageal and gastric cancer. Gut. 2002;50(Suppl. V):v1–v23
  5. Panzini I, Gianni L, Fattori PP, et al.  Adjuvant chemoterapy in gastric cancer: a meta-analysis of randomized controlled trials and a comparison with previous meta-analyses. Tumori. 2002;88:21–27
  6. Hermans J, Bonekamp JJ, Boon MC, et al.  Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomised controlled trials. J. Clin. Oncol. 1993;11(8):1441–1447
  7. Hermans J, Bonekamp H. In reply. J. Clin. Oncol. 1994;12(4):879–880
  8. Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomized trials. Eur. J. Cancer. 1999;35(7):1059–1064
  9. Mari E, Floriani I, Tinazzi A, et al.  Efficacy of adjuvant chemotherapy after curative resections for gastric cancer: a meta-analysis of randomised controlled trials. J. Clin. Oncol. 2000;11:837–843
  10. Gianni L, Panzini I, Tassinari D, et al.  Meta-analyses of randomized controlled trials of adjuvant chemotherapy in gastric cancer. Ann. Oncol. 2001;12(8):1179–1180
  11. Nakazato H, Koike A, Saji S, et al.  Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet. 1994;343:1122–1126
  12. Maehara Y, Okuyama T, Kakeji Y, et al.  Postoperative immunochemotherapy including streptococcal lysate OK-432 is effective for patients with gastric cancer and serosal invasion. Am. J. Surg. 1994;168(1):36–40
  13. Oxman AD. Systematic review: checklist for review articles. BMJ. 1994;309:648–651
  14. Gotzsche PC, Olsen O. Is screening for breast cancer with mammography justifiable. Lancet. 2000;355:129–134
  15. Macdonald JS, Smalley SR, Benedetti J, et al.  Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Eng. J. Med. 2001;345:725–730
  16. Crook PF. Gastric cancer [Diagnosis and treatment of nongynecologic cancer]. Clin. Obstet. Gynecol. 2002;45(3):892–903
  17. Bajetta E, Buzzoni R, Mariani L, et al.  Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. Ann. Oncol. 2002;13(2):299–307
  18. Metzger R, Leichman CG, Danenberg KD, et al.  ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J. Clin. Oncol. 1998;16:309–316

☆ Sources of funding: None specified.

☆☆ For correspondence: Dr J Sakamoto, Department of Epidemiological and Clinical Research Information Management, Kyoto University Graduate School of Medicine, Japan. E-mail: sakamoto@pbh.med.kyoto-u.ac.jp.

★ Abstract provided by Bazian Ltd, London.

PII: S0305-7372(02)00124-X

doi: 10.1016/S0305-7372(02)00124-X

Cancer Treatment Reviews
Volume 29, Issue 1 , Pages 73-75 , February 2003

Article Tools